Literature DB >> 21688389

Resveratrol and health--a comprehensive review of human clinical trials.

James M Smoliga1, Joseph A Baur, Heather A Hausenblas.   

Abstract

In the past decade, the small polyphenol resveratrol has received widespread attention as either a potential therapy or as a preventive agent for numerous diseases. Studies using purified enzymes, cultured cells, and laboratory animals have suggested that resveratrol has anti-aging, anti-carcinogenic, anti-inflammatory, and anti-oxidant properties that might be relevant to chronic diseases and/or longevity in humans. Although the supporting research in laboratory models is quite substantial, only recently data has emerged to describe the effects of resveratrol supplementation on physiological responses in humans. The limited number of human clinical trials that are available has largely described various aspects of resveratrol's safety and bioavailability, reaching a consensus that it is generally well-tolerated, but have poor bioavailability. Very few published human studies have explored the ability of resveratrol to achieve the physiological benefits that have been observed in laboratory models, although many clinical trials have recently been initiated. This review aims to examine the current state of knowledge on the effects of resveratrol on humans and to utilize this information to develop further guidelines for the implementation of human clinical trials.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688389     DOI: 10.1002/mnfr.201100143

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  132 in total

Review 1.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

Review 2.  Are sirtuins viable targets for improving healthspan and lifespan?

Authors:  Joseph A Baur; Zoltan Ungvari; Robin K Minor; David G Le Couteur; Rafael de Cabo
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

Review 3.  Proteostasis and REDOX state in the heart.

Authors:  Elisabeth S Christians; Ivor J Benjamin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-14       Impact factor: 4.733

4.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

5.  5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Authors:  Jonathan M Rawson; Richard H Heineman; Lauren B Beach; Jessica L Martin; Erica K Schnettler; Michael J Dapp; Steven E Patterson; Louis M Mansky
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

6.  Therapeutic effects of resveratrol in Escherichia coli-induced rat endometritis model.

Authors:  Murside Ayse Demirel; Sevtap Han; Aytekin Tokmak; Nilufer Ercan Gokay; Mecit Orhan Uludag; Tugçe Yildirir Ustun; Ali Fuat Cicek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-31       Impact factor: 3.000

7.  Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium.

Authors:  Beamon Agarwal; Matthew J Campen; Meghan M Channell; Sarah J Wherry; Behzad Varamini; James G Davis; Joseph A Baur; James M Smoliga
Journal:  Int J Cardiol       Date:  2012-10-23       Impact factor: 4.164

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 9.  Small molecule SIRT1 activators for the treatment of aging and age-related diseases.

Authors:  Basil P Hubbard; David A Sinclair
Journal:  Trends Pharmacol Sci       Date:  2014-01-16       Impact factor: 14.819

10.  Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats.

Authors:  Manar Hamed Arafa; Nanies Sameeh Mohammad; Hebatallah Husseini Atteia; Hesham Radwan Abd-Elaziz
Journal:  J Physiol Biochem       Date:  2014-06-18       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.